Skip to main navigation
Ardelyx logo2
  • Who We Are
  • Products
  • Science & Pipeline
  • Patients & Families
  • Medical Professionals
  • Investors
  • Join Us
  • MENU
  • HOME
Select Page

PRESS RELEASES

  • IR HOME
  • NEWS & EVENTS
    • OVERVIEW
    • PRESS RELEASES
    • EVENTS & PRESENTATIONS
  • STOCK INFORMATION
    • OVERVIEW
    • HISTORIC STOCK LOOKUP
    • INVESTMENT CALCULATOR
    • ANALYST COVERAGE
  • FINANCIALS & FILINGS
    • OVERVIEW
    • SEC FILINGS
  • CORPORATE GOVERNANCE
    • OVERVIEW
    • MANAGEMENT
    • BOARD OF DIRECTORS
    • COMMITTEE COMPOSITION
  • CONTACT IR
  • IR HOME
  • NEWS & EVENTS
    • OVERVIEW
    • PRESS RELEASES
    • EVENTS & PRESENTATIONS
  • STOCK INFORMATION
    • OVERVIEW
    • HISTORIC STOCK LOOKUP
    • INVESTMENT CALCULATOR
    • ANALYST COVERAGE
  • FINANCIALS & FILINGS
    • OVERVIEW
    • SEC FILINGS
  • CORPORATE GOVERNANCE
    • OVERVIEW
    • MANAGEMENT
    • BOARD OF DIRECTORS
    • COMMITTEE COMPOSITION
  • CONTACT IR

PRESS RELEASES

Press Releases
Date Title
Jun 3, 2022 Ardelyx to Present at the Jefferies 2022 Healthcare Conference
May 24, 2022 Ardelyx Presents Data at DDW 2022 on IBSRELA® (tenapanor), a First-In-Class Treatment for IBS-C in Adults
May 17, 2022 Ardelyx Announces Additional Data Supporting the Efficacy and Safety of First-In-Class IBSRELA® (tenapanor) for Adults with IBS-C, to be Presented at DDW 2022
May 16, 2022 Ardelyx, Inc. Reports Employment Inducement Grants
May 5, 2022 Ardelyx Reports First Quarter 2022 Financial Results and Recent Business Highlights
Apr 28, 2022 Ardelyx to Report First Quarter 2022 Financial Results on May 5, 2022
Apr 25, 2022 Ardelyx Announces FDA Plan to Convene Advisory Committee for XPHOZAH® (tenapanor)
Apr 12, 2022 Ardelyx, Inc. Reports Employment Inducement Grants
Apr 11, 2022 Ardelyx and Kyowa Kirin Amend License Agreement for Tenapanor
Apr 7, 2022 Ardelyx Presents Positive Data Further Supporting Efficacy and Safety of XPHOZAH® (tenapanor) at National Kidney Foundation 2022 Spring Clinical Meetings

Pagination

  • First page « first
  • Previous page ‹ previous
  • …
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Current page 6
  • Page 7
  • Page 8
  • Page 9
  • Page 10
  • …
  • Next page next ›
  • Last page last »
FAQs
Email Alerts
Connect

Bay Area
34175 Ardenwood Boulevard
Fremont, CA 94555

Greater Boston
400 Fifth Avenue, Suite 210
Waltham, MA 02451

Phone: 617.675.ARDX (2739)

Inquiries:
General: info@ardelyx.com
Media: media@ardelyx.com
Investor: investor@ardelyx.com
Business Development: partnering@ardelyx.com

  • Follow
  • Follow

© 2023 Ardelyx®
Terms & Conditions · Privacy Policy
Expanded Access · Forward Looking Statements

SITE DESIGN BY D&CO
  • Facebook
  • LinkedIn
  • Twitter
  • RSS